ATRX and neoplasm: For the low-risk cohort, the OS remained superior in the high-risk group (Fig. 4A–F) according to subgroups classified by sex, age, tumor grade, and mutational status of ATRX, EGFR, PTEN, TP53, and IDH (Additional file 5: Fig. S4).